As IL‐22 appears to induce epithelial regeneration in the intestine, it has been suggested to use this cytokine as a therapeutic agent in dysbiotic and intestinal inflammatory disorders, such as IBD or NEC. Here, IL22 is linked to inflammatory bowel disease.